Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 1162-1166

  Vernacchio, L ^a,b   Romero Steiner, S ^c   Martinez, J E ^c   MacDonald, K ^a   Barnard, S ^c   Pilishvili, T ^c   Carlone, G M ^c   Ambrosino, D M ^a   Molrine, Deborah C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; PRIORITY JOURNAL; SEROTYPE; SICKLE CELL ANEMIA;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0034083597     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315307     Document Type: Article

References (15)

1. 1. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of The Northern California Kaiser Permanente Efficacy Trial [abstract LB-9]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. Washington, DC: American Society for Microbiology, 1998.
2. 2. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101:604-11.
3. 3. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996; 122-649-53.
4. 4. Wenger JD, Steiner SR, Pais LB, et al. Laboratory correlates for protective efficacy of pneumococcal vaccines: how can they be identified and validated? [abstract G37]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Washington, DC: American Society for Microbiology, 1996:150.
5. 5. Martinez JE, Romero-Steiner S, Pilishvili T, et al. A flow cytometric opsonophagocytic assay for the measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. Clin Diagn Lab Immunol 1999;6:581-6.
6. 6. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997;4:415-22.
7. 7. Vernacchio L, Neufeld E, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998;133:275-8.
8. 8. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173:266-8.
9. 9. Quataert SA, Kirch CS, Wiedl LJQ. et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995; 2:590-7.
10. 10. Nahm MH, Olander JV, Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J Infect Dis 1997; 176:698-703.
11. 11. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999;29:281-8.
12. 12. Vidarsson G, Sigurdardottir ST, Gudnason T, et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998;66:2866-70.
13. 13. Anttila M, Eskola J, Ahman H, Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998; 177:1614-21.
14. 14. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999;67:2366-70.
15. 15. Yu X, Sun Y, Frasch C, Concepcion N, Nahm MH. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol 1999;6:519-24.